CSL Ltd
![CSL Ltd](https://api.admiralmarkets.com/trade_icons/bright-128/CSL.png)
Closed
Sector
303.69 0.59
Overview
Share price change
24h
Min
303.19
Max
304.27
Income | 1.9B |
---|---|
Sales | 8.1B |
EPS | 4.159 |
Profit margin | 23.606 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +6.31 upside |
Market Cap | -686M 148B |
---|---|
Previous open | 303.1 |
Previous close | 303.69 |
News Sentiment
By Acuity
37%
63%
92 / 382 Industrials
CSL Ltd Chart
Related News
Peer Comparison
Price change
CSL Ltd Forecast
Price Target
By TipRanks
6.31% upside
12 Months Forecast
Average 323.182 AUD 6.31%
High 352 AUD
Low 278 AUD
Based on 12 Wall Street analysts offering 12 month price targets forCSL Ltd - Dist in the last 3 months.
Sentiment
By Acuity
92 / 382
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About CSL Ltd
CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.